Spherix Global Insights Introduces New Service Focusing on Recent Launches in Expanding Immunology, Nephrology, and Neurology Markets
The Launch Dynamix™ service includes current tracking of Cosentyx (Novartis) and Taltz (Eli Lilly) in non-radiographic axial spondyloarthritis, Kesimpta (Novartis) and Zeposia (BMS) in multiple sclerosis, Stelara (Janssen) in ulcerative colitis, Tremfya (Janssen) in psoriatic arthritis, and Benlysta (GSK) and Lupkynis (Aurinia) in lupus nephritis EXTON, Pa., January 29, 2020 /PRNewswire/ —Spherix Global Insights, a […]
Unmet Need in Lupus Nephritis Finally Addressed with New FDA Approvals for GlaxoSmithKline’s BENLYSTA (belimumab) and Aurinia Pharmaceuticals’ LUPKYNIS (voclosporin)
According to Spherix Global Insights, rheumatologists and nephrologists are excited about new treatment options in addition to a multitude of pipeline compounds for patients with lupus nephritis EXTON, Pa., January 25, 2021 /PRNewswire/ —According to a survey of more than 200 US rheumatologists and nephrologists in mid-2020, the unmet need for new treatments for lupus nephritis […]
New Research on Emerging Markets in Dermatology Reveals Vast Potential for Pipeline Agents
US dermatologists’ lack of satisfaction with current treatment options in hidradenitis suppurativa and alopecia areata paves the way for advanced systemic agents to disrupt each market EXTON, Pa., January 21, 2021 /PRNewswire/ — Spherix recently surveyed 101 US dermatologists and followed up with eleven qualitative interviews (including two with industry key opinion leaders) in order to assess […]
Takeda’s Entyvio SC and Celltrion’s Remsima SC EU5 Launches Have Benefitted from Parent Brand Reputation, New Clinical Data, and COVID-19 Restraints, According to Spherix Global Insights
Entyvio SC and Remsima SC have experienced noteworthy uptake since their launches in 2020 and are positioned for continued success EXTON, Pa., January 20, 2021 /PRNewswire – Two 2020 European Medical Agency (EMA) approvals, Takeda’s Entyvio SC and Celltrion Healthcare’s infliximab biosimilar, Remsima SC, have captured notable shares among EU5 IBD patients, according to Spherix’s […]
IL-23 Inhibitors Take Over the US Psoriasis Switching Market at the Expense of the IL-17 and TNF Inhibitors
AbbVie’s Skyrizi now garners the greatest switch-to rate, capturing the majority of new business from patients previously treated with sister-brand Humira and Amgen’s Otezla EXTON, Pa., November 17, 2020 /PRNewswire/ — The 2020 audit included in Spherix’s RealWorld Dynamix™: Biologic/Small Molecule Switching in Psoriasis (US) service focuses on a critical facet of overall therapy prescribing […]
Increased Biosimilar Prescribing and New Subcutaneous Formulations Are Poised to Impact Biologic Switching in the EU Inflammatory Bowel Disease Market, According to Spherix Global Insights
Infliximab and adalimumab biosimilars continue to increase their presence in ulcerative colitis and Crohn’s disease therapy switching, while Entyvio SC and Remsima SC will cannibalize prescribing of their intravenous formulations EXTON, Pa., November 9, 2020 /PRNewswire/ — According to the latest report published as part of Spherix’s RealWorld Dynamix™: Biologic/Small Molecule Switching in IBD (EU) service, EU gastroenterologists […]
Profiling Physicians Prescribing Concurrent Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody and OnabotulinumtoxinA for Migraine Prevention: Results from an Annual US Patient Chart Audit
Authors: Robert P. Cowan, MD, FAAN; Kristen Henn, MHSc; Jennifer Robinson; Virginia R. Schobel, MSc BACKGROUND: The use of combination therapy for the preventive treatment of migraine is common. In 2018, the anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) were introduced in the US, beginning with erenumab-aooe in May, fremanezumab-vfrm in September, and galcanezumab-gnlm in […]
Trending the First Two Years of Anti-Calcitonin Gene-Related Peptide Class Availability for Migraine Prevention: Results from an Independent Quarterly US Survey of Neurologists and Migraine Specialists
Authors: Virginia R. Schobel, MSc; Kristen Henn, MHSc; Jennifer Robinson BACKGROUND: Multiple anti-calcitonin gene-related peptide (CGRP) therapies have recently been approved for the prevention of episodic and chronic migraine, including erenumab-aooe (available since May 2018), fremanezumab-vfrm (September 2018), and galcanezumab-gnlm (October 2018). Approved in February 2020, eptinezumab introduced a fourth preventive therapy to the anti-CGRP […]
Changing Patterns in Disease-Modifying Therapy Selection for Treatment-Naive Multiple Sclerosis in the United States
Authors: Patricia K. Coyle, MD; Jennifer Robinson; Virginia R. Schobel. MSc OBJECTIVE: To evaluate changes in disease-modifying therapy (DMT) choice patterns for treatment-naive multiple sclerosis (MS) in the United States from 2016 to 2019. BACKGROUND: Cross-sectional patient-level data was collected once-yearly. It was then reviewed by an independent market intelligence agency which specializes in tracking […]
Anti-CGRP Class Reduces Migraine Burden Regardless of Concomitant Therapies in US Clinical Practice
Authors: Christopher H. Gottschalk, MD, FAHS; Kristen Henn, MHS; Jennifer Robinson; Virginia R. Schobel, MSc OBJECTIVE: Assess the clinical response to anti-calcitonin gene-related peptide (CGRP) therapies across the spectrum of migraine one year after the introduction of this new class of drugs. BACKGROUND: Since 2018, three different anti-CGRP agents have been available for migraine prevention. […]
